OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10369	Companies
216098	Keywords
145810	Articles
114425	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 09/01/2025 at 18:00, 8 months 6 days ago

Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie voor de diversificatie van de kasmiddelen; closing van de transactie wordt vóór 25 september 2025 verwacht
Oxurion NV (EURONEXT BRUSSEL: OXUR) kündigt positive Finanzierungsgespräche mit Atlas Special Opportunities an. Die Transaktion wird voraussichtlich vor dem 25. September 2025 abgeschlossen sein

Atlas Special Opportunities Oxurion NV Belgien Finanzierungsgespräche Pharmaunternehmen
PRESS RELEASE

published on 09/01/2025 at 18:00, 8 months 6 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications under Belgian legislation from Atlas Special Opportunities II, LLC regarding changes in voting securities holdings

Oxurion NV Belgian Legislation Transparency Notifications Voting Securities Atlas Special Opportunities II LLC
BRIEF

published on 08/07/2025 at 18:05, 9 months ago

Oxurion reçoit des notifications de transparence d'UBS Group AG

Actions Transparence Investisseurs UBS Group AG Oxurion
BRIEF

published on 08/07/2025 at 18:05, 9 months ago

Oxurion receives transparency notifications from UBS Group AG

Investors Actions Transparency UBS Group AG Oxurion
PRESS RELEASE

published on 08/07/2025 at 18:00, 9 months ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
PRESS RELEASE

published on 08/07/2025 at 18:00, 9 months ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
PRESS RELEASE

published on 08/07/2025 at 18:00, 9 months ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
BRIEF

published on 08/06/2025 at 18:05, 9 months 1 day ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF

published on 08/06/2025 at 18:05, 9 months 1 day ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE

published on 08/06/2025 at 18:00, 9 months 1 day ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica

Accesswire

Published on 05/08/2026 at 15:00, 13 minutes ago

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Published on 05/08/2026 at 14:55, 18 minutes ago

Nepra Foods Inc. to Present at the 16th Annual LD Micro Invitational
Published on 05/08/2026 at 14:30, 43 minutes ago

Unusual Machines Hosts Live Drone Ecosystem Demonstrations at XPONENTIAL 2026
Published on 05/08/2026 at 14:00, 1 hour 13 minutes ago

BlackBerry Announces Renewal of Normal Course Issuer Bid Share Buyback Program
Published on 05/08/2026 at 14:00, 1 hour 13 minutes ago

Loop Industries to Host Fourth Quarter 2025 Earnings Conference Call

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 15:08, 5 minutes ago

Siltronic AG's Annual General Meeting approves all agenda items by a clear majority
Published on 05/08/2026 at 14:16, 57 minutes ago

Porsche sharpens focus on core business
Published on 05/08/2026 at 13:53, 1 hour 20 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/08/2026 at 13:35, 1 hour 38 minutes ago

DeFi Technologies Announces Partnership with OMFIF's Digital Monetary Institute and Confirms Participation at the Digital Money Summit 2026 in London
Published on 05/08/2026 at 13:05, 2 hours 8 minutes ago

Philadelphia Soccer 2026 Opens Media Credentialing and Fan Registration for FIFA Fan Festival™ Philadelphia

Les Echos

Published on 05/07/2026 at 19:15, 19 hours 58 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 19 hours 58 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 20 hours 7 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 20 hours 7 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 20 hours 13 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE